Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib

Journal of Clinical Oncology

Volumn 28, Issue 23, 2010, Pages

  Cleary, James M ^a,b   Sadow, Peter M ^a   Randolph, Gregory W ^a,b   Palmer, Edwin L ^a   Lynch, Thomas P ^a,c   Nikiforov, Yuri E ^d   Wirth, Lori J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c YALE CANCER CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; ASPIRATION BIOPSY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; MEDULLARY CARCINOMA; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PYRROLES; THYROID NEOPLASMS;

EID: 77957276960     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.4225     Document Type: Article

References (16)

1. Wells SA Jr, Gosnell JE, Gagel RF, et al: Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial. J Clin Oncol 25:303s, 2007 (abstr 6018)
2. Kober F, Hermann M, Handler A, et al: Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 25:617s, 2007 (abstr 14065)
3. Haddad RI, Krebs AD, Vasselli J, et al: A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26:322s, 2008 (abstr 6024)
4. Schlumberger MJ, Elisei R, Bastholt L, et al: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801, 2009
5. Salgia R, Sherman S, Hong DS, et al: A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 26:158s, 2008 (abstr 3522)
6. WHO Classification of Tumours: Pathology & Genetics: Tumours of the Endocrine Organs, in DeLellis RA LR, Heitz PU, Eng C (ed): World Health Organization Classification of Tumours. Lyon, France, IARC Press, 2004, pp 77-81
7. Cohen EG, Shaha AR, Rinaldo A, et al: Medullary thyroid carcinoma. Acta Otolaryngol 124:544-557, 2004 (Pubitemid 38858220)
8. Donis-Keller H, Dou S, Chi D, et al: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856, 1993 (Pubitemid 23216611)
9. Mulligan LM, Kwok JB, Healey CS, et al: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460, 1993 (Pubitemid 23179393)
10. Eng C, Mulligan LM, Smith DP, et al: Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12:209-212, 1995
11. Rekhi B, Kane SV, D'Cruz A: Cytomorphology of anaplastic giant cell type of medullary thyroid carcinoma-a diagnostic dilemma in an elderly female: A case report. Diagn Cytopathol 36:136-138, 2008 (Pubitemid 351161907)
12. Grimaldi AM, Guida T, D'Attino R, et al: Sunitinib: Bridging present and future cancer treatment. Ann Oncol 18:vi31-4, 2007 (suppl 6)
13. Kim DW, Jo YS, Jung HS, et al: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076, 2006 (Pubitemid 44536887)
14. Kelleher FC, McDermott R: Response to sunitinib in medullary thyroid cancer. Ann Intern Med 148:567, 2008 (Pubitemid 351665439)
15. Berard I, Kraimps JL, Savagner F, et al: Germline-sequence variants S836S and L769L in the RE arranged during transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population. Clin Genet 65:150-152, 2004 (Pubitemid 38220117)
16. Wiench M, Wloch J, Wygoda Z, et al: RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma. Cancer Detect Prev 28:231-236, 2004 (Pubitemid 40125372)